infohep news

• COVID-19 vaccine protection is ‘lower and slower’ in people with cirrhosis

  Keith Alcorn / 22 November 2021

  People with cirrhosis of the liver may take longer to achieve protection from SARS-CoV-2 and severe COVID-19 after vaccination, according to large studies in the United States and Chile, presented earlier this month ...

• Coronavirus

  People with liver cirrhosis have weaker responses to the Pfizer and Moderna SARS-CoV-2 vaccines

  Keith Alcorn / 16 November 2021

  People with cirrhosis of the liver had delayed and suboptimal responses to the Pfizer or Moderna SARS-CoV-2 vaccines compared to healthy adults, an Italian study has found. People with decompensated cirrhosis had significantly ...

• Coronavirus

  Treatment for hepatitis B and C fell in 2020 due to COVID-19, global survey finds

  Keith Alcorn / 16 November 2021

  Viral hepatitis tests and treatment declined significantly during 2020 as a consequence of the COVID-19 pandemic, a survey of 31 liver centres on five continents has shown. The decline in testing and ...

• Hepatitis C elimination

  Hepatitis C elimination: less than 25% of people with hepatitis C diagnosed globally

  Keith Alcorn / 15 November 2021

  The global prevalence of hepatitis C has declined since 2015, partly due to scale-up of direct-acting antiviral treatment, but fewer than one in four people with hepatitis C has been diagnosed, ...

• Hepatitis C elimination

  Hepatitis C treatment in US declined from 2015 to 2020

  Liz Highleyman / 14 November 2021

  From a height of more than 164,000 in 2015, the number of people treated with direct-acting antiviral (DAA) therapy for hepatitis C has steadily declined, reaching a low point during the COVID-19 pandemic, ...